Answers are grounded in this paper and cite their sources.
Observational analysis demonstrates frequent exacerbations alongside elevated eosinophil counts in patients with COPD on triple therapy, suggesting a role for targeted biologic treatment.
Nearly one-quarter of patients receiving triple therapy for COPD who experienced frequent exacerbations had elevated BEC and ≥3 exacerbations, suggesting a potential mechanism of persistent eosinophilic inflammation that could be a target for eosinophil-depleting biologic therapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: